Illing Rowland, Emberton Mark
The Clinical Effectiveness Unit, The Royal College of Surgeons of England, 35/43 Lincolns Inn Fields, London, UK.
Expert Rev Med Devices. 2006 Nov;3(6):717-29. doi: 10.1586/17434440.3.6.717.
Prostate cancer (PCa) is the most common cancer in men and the second leading cause of death from malignancy in the UK. The number of men diagnosed with PCa is increasing, due in part to an increased willingness of men to visit their family doctors with lower urinary tract symptoms, and also a willingness of physicians to test for it. As the demographic of men diagnosed with PCa becomes younger and better informed, so the demand for a less-invasive alternative to standard therapies becomes greater. The Sonablate-500 is one of only two high-intensity focused ultrasound (HIFU) devices commercially available to treat PCa. HIFU is an attractive treatment option as it is the only form of therapy that neither involves direct instrumentation of the prostate nor ionizing radiation. This article describes the unique features of both the Sonablate-500 system hardware and software, and the outcome data from this device in the context of current standard therapies. Finally, a view into the future attempts to outline where this technology is heading and how a paradigm shift in the way that PCa is considered may make HIFU even more relevant.
前列腺癌（PCa）是男性中最常见的癌症，在英国是恶性肿瘤导致死亡的第二大原因。被诊断出患有前列腺癌的男性人数正在增加，部分原因是男性更愿意因下尿路症状去看家庭医生，并且医生也更愿意进行相关检测。随着被诊断出患有前列腺癌的男性群体越来越年轻且信息更灵通，对标准疗法的侵入性较小的替代方案的需求也越来越大。Sonablate - 500是市面上仅有的两种可用于治疗前列腺癌的高强度聚焦超声（HIFU）设备之一。HIFU是一种有吸引力的治疗选择，因为它是唯一一种既不涉及对前列腺进行直接器械操作也不涉及电离辐射的治疗方式。本文描述了Sonablate - 500系统硬件和软件的独特特性，以及在当前标准疗法背景下该设备的疗效数据。最后，展望未来，试图概述这项技术的发展方向，以及前列腺癌认知方式的范式转变如何可能使HIFU变得更加重要。
